How Definium Therapeutics, Inc. stacks up

DFTX · against 588 other Healthcare companies listed in US-listed

Valuation

33/ 100

Below the middle of the pack.

Ranked #254 of 589 · scores higher than 50% of peers

Bars: peers in each 10-point band of the valuation score

75 peers with a valuation score of 30–39, including DFTX · Click a bar to see the companies

Why valuation scores 33?

Weighted metrics compared with all Healthcare companies.

Mainly because of its earnings yield, which is weaker than most Healthcare peers.

Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -7.9% vs peer median 1.5%
Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -3.7% vs peer median 0.0%
EBITDA yield is not reported, so it is left out of the score.

Metric by metric

Position: dot = DFTX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.

Metric	DFTX	Peer median	Better than	Position among peers	Weight
Earnings yieldHigher is better · 577 reported	-10.3%	-4.3%	35%		30%
EBITDA yieldHigher is better · 578 reported	Not reported	-0.8%	—	—	50%
Free cash flow yieldHigher is better · 553 reported	-3.7%	-2.3%	44%		20%
Book yieldHigher is better · 587 reported	20.5%	25.9%	43%		Context only

A metric that is not reported is left out of the score; the other weights are rescaled.

Ranking by valuation score

Top 5 and the companies ranked around DFTX

Rank	Company	Market cap	Valuation	Overall
1	Clinuvel Pharmaceuticals LimitedCUVL · US-listed	256M USD	98	80
2	Arbutus Biopharma CorporationABUS · US-listed	595M USD	96	97
2	CorMedix Inc.CRMD · US-listed	433M USD	96	81
2	Community Health Systems, Inc.CYH · US-listed	289M USD	96	57
2	InMode Ltd.INMD · US-listed	810M USD	96	69
⋯
254	BioAge Labs, Inc.BIOA · US-listed	274M USD	33	57
254	Belite Bio, IncBLTE · US-listed	6.1B USD	33
254	Perspective Therapeutics, Inc.CATX · US-listed	100M USD	33	37
254	Cellectis S.A.CLLS · US-listed	110M USD	33	38
254	Definium Therapeutics, Inc.DFTX · US-listed	4.5B USD	33	33
254	Bright Minds Biosciences Inc.DRUG · US-listed	213M USD	33
254	enGene Therapeutics Inc.ENGN · US-listed	109M USD	33	47
254	Evommune, Inc.EVMN · US-listed	216M USD	33	44
254	EyePoint, Inc.EYPT · US-listed	34M USD	33	19

Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score

Bringing the fundamentals into focus…